Dr. Remington Nevin


Dr. Remington Lee Nevin is a consulting physician epidemiologist board certified in Public Health and General Preventive Medicine by the American Board of Preventive Medicine and Certified in Public Health by the National Board of Public Health Examiners.  Dr. Nevin specializes in the evaluation of adverse reactions to antimalarial medications, particularly the neurotoxic quinoline derivative mefloquine (previously marketed in the United States as Lariam®).

A former U.S. Army Major and Preventive Medicine Officer with extensive travel medicine and policy experience, he focuses his current research in the Department of Mental Health at the Johns Hopkins Bloomberg School of Public Health on understanding the mechanisms and clinical effects of antimalarial drug toxicity, and translating the results into recommendations to better inform the rational use of these drugs.

Dr. Nevin’s work has been instrumental in improving policymakers’ and the public’s understanding of the potential for permanent neurologic and long-lasting psychiatric effects from quinoline derivative antimalarials, as exemplified by the recent FDA “black box” warning for mefloquine, and the U.S. Army Special Forces’ ban on its use among elite combat troops. Dr. Nevin has also advocated for improvements to Peace Corps mefloquine policy to better protect the health of volunteers at risk of exposure to the drug.

Dr. Nevin was first to publish clinical descriptions of the lasting toxic syndromes of brain and brainstem injury caused by the use of mefloquine, including limbic encephalopathy and neurotoxic vestibulopathy, and has collaborated on the first review of the drug’s effects published in the forensic psychiatry literature. Dr. Nevin has testified before the U.S. Senate and the U.K. Parliament on the drug’s strong ties to suicide and violence, and the drug’s lasting neurologic and psychiatric effects confounding the diagnosis and management of posttraumatic stress disorder and traumatic brain injury.